Paul W.G. Wijnhoven
AstraZeneca (United Kingdom)(GB)
Publications by Year
Research Areas
PARP inhibition in cancer therapy, DNA Repair Mechanisms, CRISPR and Genetic Engineering, Cell death mechanisms and regulation, Cancer-related Molecular Pathways
Most-Cited Works
- → p53 induces formation of NEAT1 lncRNA-containing paraspeckles that modulate replication stress response and chemosensitivity(2016)467 cited
- → AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity(2019)327 cited
- → Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer(2017)273 cited
- → Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells(2020)182 cited
- → Systematic characterization of deubiquitylating enzymes for roles in maintaining genome integrity(2014)148 cited
- → Synthetic lethality between PAXX and XLF in mammalian development(2016)89 cited
- → Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance(2022)82 cited
- → USP4 Auto-Deubiquitylation Promotes Homologous Recombination(2015)77 cited
- → The deubiquitylating enzyme UCHL3 regulates Ku80 retention at sites of DNA damage(2018)48 cited
- → Radiopotentiation Profiling of Multiple Inhibitors of the DNA Damage Response for Early Clinical Development(2021)21 cited